Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Brain Over Muscle Mutations in the gene encoding the Kir6.2 subunit of the adenosine triphosphate (ATP)–sensitive potassium (K ATP ) channel cause a specific type of neonatal diabetes in humans, known as iDEND, which is often accompanied by muscle weakness of unknown etiology. By studying mice expressing the mutant gene only in muscle or only in nerve, Clark et al. (p. 458 , published online 1 July) found that the motor impairments originate from inappropriate activation of the channel in the central nervous system rather than in muscle. Patients with iDEND are often treated with sulphonylurea therapies that block K ATP channels in both brain and muscle, and these drugs can have adverse effects on heart muscle. Drugs with greater specificity for K ATP channels in the brain may thus be a safer option.

More information Original publication

DOI

10.1126/science.1186146

Type

Journal article

Publisher

American Association for the Advancement of Science (AAAS)

Publication Date

2010-07-23T00:00:00+00:00

Volume

329

Pages

458 - 461

Total pages

3